Catalog classification, reference sizes, lab math links, and source-backed data. Educational use only — not medical advice.
Researched for: PepTools vendor-neutral scientific reference catalog
Also known as: GLP-1 RAs, GLP-1 receptor agonists, glucagon-like peptide-1 receptor agonists, incretin mimetics
This entry is a multi-compound blend. Each component can be opened individually in the reconstitution calculator.
Component amounts shown are arithmetic starters based on equal distribution. Edit values in the calculator before saving.
GLP-1 receptor agonists are synthetic peptide analogs or other receptor agonists that activate the GLP-1 receptor. Class effects described in authoritative pharmacology literature include glucose-dependent stimulation of insulin secretion, suppression of glucagon secretion during normoglycemia or hyperglycemia, slowing of gastric emptying, and reduction of calorie intake. Molecular strategies used to extend activity include resistance to dipeptidyl peptidase-4 degradation, fatty-acid conjugation, albumin binding, and fusion to larger protein domains. The class includes short-acting, once-daily, and once-weekly agents; oral formulations are available for some members.
Source review pending. This descriptive profile is shown from the available source material as a best-effort educational reference. It has not passed the full verification bar and is not a dosing instruction, medical claim, or treatment recommendation.
Data source: Primary literature, regulator records, trial registries, and identity-specific evidence search
Reflects preclinical/research literature context only. Not a medical claim, dosing instruction, or treatment recommendation.
Evidence-backed administration schedules vary by individual agent and formulation, including twice-daily, once-daily, and once-weekly regimens. Because this record represents a heterogeneous class, agent-specific dose, route, timing, half-life, formulation, stability, and storage data should be maintained in separate compound records. FDA materials identify exenatide, lixisenatide, liraglutide, dulaglutide, semaglutide, and related products as GLP-1 receptor agonist medicines; albiglutide is a historical member. Tirzepatide should be classified separately or cross-referenced as a dual GLP-1/GIP receptor agonist.
Supplementary research context only. Not medical advice or a treatment recommendation.
No single CAS Registry Number, UNII, InChIKey, or molecular formula applies to the class. Individual GLP-1 receptor agonists have separate chemical identifiers.
This is a pharmacological class rather than one chemically uniform compound. Native human GLP-1 has an extremely short circulating half-life of approximately 2 minutes, whereas engineered agonists have substantially prolonged exposure. Tirzepatide is pharmacologically related but is a dual GLP-1/GIP receptor agonist rather than a selective GLP-1 receptor agonist.
Reflects published research. Educational reference — not a recommendation for use.
Found a relevant Reddit or forum thread about this compound? Suggest it below. Every suggestion is reviewed by an editor before it appears -- nothing is published automatically.
Published articles on this site that mention GLP-1 receptor agonists or one of its catalog aliases.
Research Use Only. All content is for educational and research reference only. Not medical advice, a treatment recommendation, or guidance on human use. Compounds are not FDA-approved drugs unless specifically noted.